$SRPT

Genmab and AbbVie's Epkinly showed promising results in a Phase 3 study, reducing disease progression or death risk by 51% in lymphoma patients. IntraBio was acquired by Shionogi for $2 billion, expanding Aqneursa's approvals. Novartis invested up to $7.8 billion in Abogen Biosciences. Eli Lilly and CSL also announced significant biopharma deals. Sarepta Therapeutics presented positive Elevidys data, with upcoming catalysts for its treatments.

Sarepta Therapeutics (SRPT) will present data on its gene therapies at a neuromuscular meeting, including Phase 4 results for ELEVIDYS (delandistrogene moxeparvovec) and interim findings for SRP-1003 and SRP-1001. The presentations cover safety, efficacy, and real-world analyses. ELEVIDYS is approved for Duchenne muscular dystrophy but carries risks of liver injury.

Sarepta Therapeutics, Inc. (SRPT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026 (the “Effective Date”), Sarepta Therapeutics, Inc. (the “Company”), Sarepta Therapeutics Three, LLC (“Sarepta Three” and, together with the Company, “Sarepta”), REGENXBIO Inc. (“REGENXBIO”), the Trustees

A KFF Health News analysis found nearly 600 postmarket drug studies delayed, involving 350 products. Many remain on the market without completed safety or effectiveness research. Amgen's Tavneos and Sarepta's Exondys 51 are among the delayed studies. HHS notes delays don't necessarily indicate safety issues but require case-specific review.

Sarepta Therapeutics (SRPT) expects ELEVIDYS demand to stabilize, with second-half 2026 sales modestly below first-half levels. The company is conducting studies on non-ambulatory patients and advancing FSHD and DM1 programs, with readouts expected in late 2026. Sarepta also discussed its PMO franchise's competitive position and upcoming potential competition. Key data points include potential 50% reduction in acute liver injury and over 90% correction in DUX4 gene-regulated panels.

Novartis' Phase 3 trial of del-desiran for myotonic dystrophy type 1 failed to meet its primary endpoint, video hand opening time. The company will review data and consult regulators. Del-desiran is not yet approved, and no treatment timeline is set. Novartis shares fell, along with those of Dyne and Sarepta, which are developing similar therapies.

Novartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.

Jefferies reiterated a Buy rating and $30.00 price target for Sarepta Therapeutics (SRPT), citing potential 40% upside. The firm expects Phase I/II trial data in 2H 2026, with competitive results potentially driving significant stock movement. SRPT reported Q2 2026 earnings beating estimates, with EPS of $0.64 vs. $0.22 forecasted and revenue of $401.3M vs. $383M expected. Mizuho also reiterated an Outperform rating with a $31.00 target.

Sarepta Therapeutics (SRPT) stock fell 8.09% after Novartis (NVS) reported Phase 3 trial results for del-desiran in myotonic dystrophy type 1 (DM1) that did not meet primary endpoints. Sarepta is developing SRP-1003 for DM1, with Phase 1/2 data expected in late 2026. The company noted positive early data and potential for optimized dosing. SRPT is above short-term moving averages but below the 200-day SMA, indicating mixed signals.

Mizuho reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (SRPT), stating the sell-off after Novartis' failed trial is excessive. The firm noted that Novartis' del-desiran showed clinical activity in secondary endpoints, which may aid Sarepta's SRP-1003 development. SRPT stock fell 10% following the news but remains up 35% over six months. The company recently reported Q2 2026 earnings of $0.64 per share, exceeding estimates, with revenue at $401.3 million.